Covid-19: current knowledge, disease potential, prevention and clinical advances

Öz The top priority of any nation is to lead the nation towards prosperity, progress, and economic growth, confronting several challenges and concerns arisen from global situations. The sudden outbreak of any disease defies the health care systems and economy of nations. COVID-19 is one of the viral diseases which broke out in Wuhan city of China in 2019. COVID-19 outbreak intermittently prevailed all over the world. It exposes the fragility of the established health care systems across the world in spite of comprising modern science and technology. Unfortunately, there is no chemotherapeutic agent in the regimen of antiviral drugs or no vaccine available to curb this infectious disease. As a consequence, this deadly infection has prevailed all over the world. The antiviral drugs used for viral diseases excluding COVID-19 infection are Ramdesvir, Favipiravir, and Ribavarin, and antimalarial agents (Chloroquine & Hydroxychloroquine) are being administered to the patients for redemption of this infection. Fortunately, these existing drugs have been found clinically active and are being used. In this review, we present the current scenario and status of epidemiology, diagnosis, treatment, vaccine development for COVID-19, and its impact on the socio-economic structure.

Kaynakça

Alam A, 2017, BIOMED PHARMACOTHER, V91, P1152, DOI 10.1016/j.biopha.2017.05.045

Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0

Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13

Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14

Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9

Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7

Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011

Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07

Chhikara B. S., 2020, CHEM BIOL LETT, V7, P63, DOI DOI 10.1007/s00058-020-1496-8

Cohen FS, 2016, BIOPHYS J, V110, P1028, DOI 10.1016/j.bpj.2016.02.006

Cohen J, 2020, SCIENCE, DOI [10.1126/science.abb0611, DOI 10.1126/SCIENCE.ABB0611]

Cyranoski David, 2020, Nature, DOI 10.1038/d41586-020-00364-2

De Clercq E, 2019, CHEM-ASIAN J, V14, P3962, DOI 10.1002/asia.201900841

de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25

de Wilde AH, 2017, VIRUS RES, V228, P7, DOI 10.1016/j.virusres.2016.11.011

de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81

Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868

Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362

Gorbalenya A. E., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862, 10.1101/2020.02.07.937862v1]

Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0

Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191

Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5

Ito K, 2016, J GASTROEN HEPATOL, V31, P180, DOI 10.1111/jgh.13030

Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682

Ju J, 2020, BIORXIV, DOI [10.1101/2020.03.12.989186, DOI 10.1101/2020.03.12.989186]

Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002

Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14

Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0

Li Hongying, 2019, Biosaf Health, V1, P84, DOI 10.1016/j.bsheal.2019.10.004

Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8

Magagnoli Joseph, 2020, medRxiv, DOI [10.1016/j.medj.2020.06.001, 10.1101/2020.04.16.20065920]

Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047

Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010

O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09

Oberg B, 2006, ANTIVIR RES, V71, P90, DOI 10.1016/j.antiviral.2006.05.012

Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331

Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014

Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6

Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0

Wang N, 2018, VIROL SIN, V33, P104, DOI 10.1007/s12250-018-0012-7

Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689

Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027

Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011

Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37

Kaynak Göster

Bibtex @araştırma makalesi { tbtkbiology943532, journal = {Turkish Journal of Biology}, issn = {1300-0152}, eissn = {1303-6092}, address = {}, publisher = {TÜBİTAK}, year = {2020}, volume = {44}, pages = {121 - 131}, doi = {}, title = {Covid-19: current knowledge, disease potential, prevention and clinical advances}, key = {cite}, author = {Alam, Aftab and Siddiqui, Mohd Faizan and Imam, Nikhat and Ali, Rafat and Mushtaque, Md and Ishrat, Romana} }
APA Alam, A , Siddiqui, M , Imam, N , Ali, R , Mushtaque, M , Ishrat, R . (2020). Covid-19: current knowledge, disease potential, prevention and clinical advances . Turkish Journal of Biology , Special Issue on COVID-19 , 121-131 .
MLA Alam, A , Siddiqui, M , Imam, N , Ali, R , Mushtaque, M , Ishrat, R . "Covid-19: current knowledge, disease potential, prevention and clinical advances" . Turkish Journal of Biology 44 (2020 ): 121-131 <
Chicago Alam, A , Siddiqui, M , Imam, N , Ali, R , Mushtaque, M , Ishrat, R . "Covid-19: current knowledge, disease potential, prevention and clinical advances". Turkish Journal of Biology 44 (2020 ): 121-131
RIS TY - JOUR T1 - Covid-19: current knowledge, disease potential, prevention and clinical advances AU - Aftab Alam , Mohd Faizan Siddiqui , Nikhat Imam , Rafat Ali , Md Mushtaque , Romana Ishrat Y1 - 2020 PY - 2020 N1 - DO - T2 - Turkish Journal of Biology JF - Journal JO - JOR SP - 121 EP - 131 VL - 44 IS - SI-1 SN - 1300-0152-1303-6092 M3 - UR - Y2 - 2020 ER -
EndNote %0 Turkish Journal of Biology Covid-19: current knowledge, disease potential, prevention and clinical advances %A Aftab Alam , Mohd Faizan Siddiqui , Nikhat Imam , Rafat Ali , Md Mushtaque , Romana Ishrat %T Covid-19: current knowledge, disease potential, prevention and clinical advances %D 2020 %J Turkish Journal of Biology %P 1300-0152-1303-6092 %V 44 %N SI-1 %R %U
ISNAD Alam, Aftab , Siddiqui, Mohd Faizan , Imam, Nikhat , Ali, Rafat , Mushtaque, Md , Ishrat, Romana . "Covid-19: current knowledge, disease potential, prevention and clinical advances". Turkish Journal of Biology 44 / SI-1 (Haziran 2020): 121-131 .
AMA Alam A , Siddiqui M , Imam N , Ali R , Mushtaque M , Ishrat R . Covid-19: current knowledge, disease potential, prevention and clinical advances. Turkish Journal of Biology. 2020; 44(SI-1): 121-131.
Vancouver Alam A , Siddiqui M , Imam N , Ali R , Mushtaque M , Ishrat R . Covid-19: current knowledge, disease potential, prevention and clinical advances. Turkish Journal of Biology. 2020; 44(SI-1): 121-131.
IEEE A. Alam , M. Siddiqui , N. Imam , R. Ali , M. Mushtaque ve R. Ishrat , "Covid-19: current knowledge, disease potential, prevention and clinical advances", Turkish Journal of Biology, c. 44, sayı. SI-1, ss. 121-131, Haz. 2020
  • ISSN: 1300-0152
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK

10.4b 5.5b

Sayıdaki Diğer Makaleler

Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties

Erman Salih ISTİFLİ, Arzuhan Sihoglu TEPE, Cengiz SARİKURKCU, Bektas TEPE

Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey

Ayse Banu DEMİR, Domenico BENVENUTO, Hakan ABACİOGLU, Silvia ANGELETTİ, Massimo CİCCOZZİ

Phylogenetic analysis of SARS-CoV-2 genomes in Turkey

Ogun ADEBALİ, Aylin BİRCAN, Defne CİRCİ, Burak ISLEK, Zeynep KİLİNC, Berkay SELCUK, Berk TURHAN

Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review

Tauseef AHMAD, Haroon HAROON, Kuldecip DHAMA, Khan SHARUN, Fazal Mehmood KHAN, Irfan AHMED, Ruchi TİWARİ, Taha Hussien MUSA, Muhammad KHAN, D. Katterine BONİLLA-ALDANA, Alfonso J. RODRİGUEZ-MORALES, Jin HUİ

Potentials of plant-based substance to inhabit and probable cure for the COVID-19

Israt JAHAN, Ahmet ONAY

Covid-19: current knowledge, disease potential, prevention and clinical advances

Aftab ALAM, Mohd Faizan SİDDİQUİ, Nikhat IMAM, Rafat ALİ, Md MUSHTAQUE, Romana ISHRAT

Gut-lung axis and dysbiosis in COVID-19

Busra AKTAS, Belma ASLIM

Integration of transcriptomic profile of SARS-CoV-2 infected normal human bronchial epi-thelial cells with metabolic and protein-protein interaction networks

Hamza Umut KARAKURT, Pinar PİR

SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients

Cihan TASTAN, Bulut YURTSEVER, Gozde Sir KARAKUS, Derya Dilek KANCAGİ, Sevda DEMİR, Selen ABANUZ, Utku SEYİS, Mulazim YİLDİRİM, Recai KUZAY, Omer ELİBOL, Serap ARBAK, Merve Acikel ELMAS, Selcuk BİRDOGAN, Osman Ugur SEZERMAN, Aye Sesin KOCAGOZ, Koray YALCİN, Ercument OVALİ

An updated analysis of variations in SARS-CoV-2 genome

Osman Mutluhan UGUREL, Oguz ATA, Dilek TURGUT-BALİK